About
Ritter's lead compound, RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance. RP-G28 has successfully completed Phase 2a clinical trials, and Ritter Pharma plans to partner the drug.
Ritter's lead compound, RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance. RP-G28 has successfully completed Phase 2a clinical trials, and Ritter Pharma plans to partner the drug.